Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive steroid, which is in Phase III clinical trials for treating PPD, major depressive disorders, treatment resistant disorders, generalized anxiety disorders, and bipolar depression; and SAGE-324, a …
Over the last 12 months, insiders at Sage Therapeutics, Inc. have bought $0 and sold $0 worth of Sage Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Sage Therapeutics, Inc. have bought $1.39M and sold $519,413 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 2,000 shares for transaction amount of $37,279 was made by Barrett Elizabeth (director) on 2023‑08‑09.
2023-08-09 | director | 2,000 0.0032% | $18.64 | $37,279 | +3.37% | |||
2023-05-09 | director | 1,000 0.0017% | $50.50 | $50,500 | -58.11% | |||
2023-02-10 | Sale | director | 11,643 0.0193% | $44.61 | $519,413 | -41.08% | ||
2022-11-10 | President and CEO | 14,500 0.024% | $34.48 | $500,022 | +19.18% | |||
2022-05-05 | 8,000 0.0136% | $31.45 | $251,563 | +26.48% | ||||
2021-08-05 | President and CEO | 23,640 0.0401% | $43.15 | $1.02M | -10.58% | |||
2021-06-16 | director | 17,842 0.0311% | $56.05 | $999,983 | -24.87% | |||
2021-06-16 | President and CEO | 8,800 0.0154% | $56.32 | $495,627 | -24.87% | |||
2021-06-16 | director | 1,810 0.0031% | $55.10 | $99,735 | -24.87% | |||
2019-12-09 | Chief Scientific Officer | 25,000 0.0494% | $64.16 | $1.6M | -16.96% | |||
2019-12-09 | President & CEO | 7,500 0.0148% | $64.20 | $481,500 | -16.96% | |||
2019-08-15 | Sale | director | 8,000 0.0154% | $160.58 | $1.28M | -58.68% | ||
2019-05-29 | Sale | President & CEO | 1,075 0.0021% | $170.61 | $183,401 | -20.75% | ||
2019-05-28 | Sale | President & CEO | 84,661 0.1656% | $174.83 | $14.8M | -20.45% | ||
2019-05-24 | Sale | President & CEO | 40,356 0.0786% | $175.08 | $7.07M | -20.51% | ||
2019-05-23 | Sale | President & CEO | 53,908 0.1047% | $174.51 | $9.41M | -20.45% | ||
2019-05-22 | Sale | Chief Business Officer | 25,000 0.0485% | $175.00 | $4.38M | -20.71% | ||
2019-05-10 | Sale | SVP, GC & Secretary | 15,000 0.0293% | $166.14 | $2.49M | -15.12% | ||
2019-05-06 | Sale | director | 8,000 0.0148% | $162.22 | $1.3M | -17.11% | ||
2019-03-21 | Sale | director | 7,879 0.0166% | $161.04 | $1.27M | -1.30% |
STARR KEVIN P | director | 320659 0.5242% | $6.00 | 1 | 4 | <0.0001% |
Robichaud Albert | Chief Scientific Officer | 136400 0.223% | $6.00 | 2 | 6 | +14.96% |
PAUL STEVEN M | director | 122400 0.2001% | $6.00 | 1 | 14 | +46.89% |
JONAS JEFFREY M | director | 121981 0.1994% | $6.00 | 3 | 10 | <0.0001% |
Greene Barry E | President and CEO | 46940 0.0767% | $6.00 | 3 | 0 | <0.0001% |
Fidelity Investments | $109.97M | 9.75 | 5.87M | +7.04% | +$7.23M | 0.01 | |
The Vanguard Group | $107.78M | 9.56 | 5.75M | +8.12% | +$8.1M | <0.01 | |
RTW Investments, LP | $102.71M | 9.11 | 5.48M | +5.46% | +$5.31M | 1.54 | |
BlackRock | $91.68M | 8.13 | 4.89M | +4.89% | +$4.28M | <0.01 | |
Wellington Management Company | $89.06M | 7.9 | 4.75M | -21.61% | -$24.55M | 0.02 |